Skip to main content Scroll Top

News

  • Home
  • Videos
  • Brain-Gut Photobiomodulation: Preclinical and Clinical Studies for Alzheimer’s Disease.
Most Viewed Posts
Clear Filters
REGENLIFE: “Product or service of the future” award, Les Inn’Ovations 2019 competition
SilverEco Awards
Be 2 Sport Webinar

Brain-Gut Photobiomodulation: Preclinical and Clinical Studies for Alzheimer’s Disease.

Guillaume Blivet, Chief Innovation Officer at REGEnLIFE, presented at the Mass General Hospital, Brain PBM Clinic Rounds (12.08.23) on their preclinical and clinical studies assessing Transcranial and Gut Photobiomodulation as a treatment for Alzheimer’s Disease.

Share this article